(Utkast) Kommisjonens gjennomføringsforordning (EU) .../... om endring av gjennomføringsforordning (EU) nr. 540/2011 med hensyn til forlengelse av godkjenningsperiodene for de aktive stoffene aklonifen, amisulbrom, Bacillus amyloliquefaciens-stamme MBI 600, beflubutamid, klomazon, cyantraniliprol, cyprodinil, daminozid, diklorprop-P, dimetaklor, fludioksonil, formetanat, fosetyl, isofetamid, metalaksyl, metazaklor, penkonazol, fenmedifam, pirimikarb, pyraklostrobin og S-abscisinsyre
Plantevernmidler: endringsbestemmelser om forlengelse av godkjenningsperioden til aclonifen, amisulbrom m.fl.
(Draft) Commission Implementing Regulation (EU) .../... amending Implementing Regulation (EU) No 540/2011 as regards the extension of the approval periods of the active substances aclonifen, amisulbrom, Bacillus amyloliquefaciens strain MBI 600, beflubutamid, clomazone, cyantraniliprole, cyprodinil, daminozide, dichlorprop-P, dimethachlor, fludioxonil, formetanate, fosetyl, isofetamid, metalaxyl, metazachlor, penconazole, phenmedipham, pirimicarb, pyraclostrobin and S-abscisic acid
Utkast til kommisjonsforordning godkjent av komite (representanter for medlemslandene) og publisert i EUs komitologiregister 10.7.2026
Bakgrunn
(fra kommisjonsforordningen)
(1) The active substances aclonifen, amisulbrom, Bacillus amyloliquefaciens strain MBI 600, beflubutamid, clomazone, cyantraniliprole, cyprodinil, daminozide, dichlorpropP, dimethachlor, fludioxonil, formetanate, fosetyl, isofetamid, metalaxyl, metazachlor, penconazole, phenmedipham, pirimicarb, pyraclostrobin and S-abscisic acid were approved as active substances for use in plant protection products for a limited period of time and the applications for the renewal of their approvals are currently being evaluated pursuant to Article 14 of Regulation (EC) No 1107/2009.
(2) Commission Directive 2004/30/EC2 included pyraclostrobin in Annex I to Council Directive 91/414/EEC as an active substance until 31 May 2014 and it was subsequently included in Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011. The approval of pyraclostrobin was extended ten times, most recently by Commission Implementing Regulation (EU) 2025/1489 until 15 September 2026.
(3) Commission Directive 2004/58/EC included phenmedipham in Annex I to Council Directive 91/414/EEC as an active substance until 28 February 2015 and it was subsequently included in Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011. The approval of phenmedipham was extended nine times, most recently by Commission Implementing Regulation (EU) 2025/99 until 30 September 2026.
(4) Commission Directive 2005/53/EC included daminozide in Annex I to Council Directive 91/414/EEC as an active substance until 28 February 2016 and it was subsequently included in Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011. The approval of daminozide was extended nine times, most recently by Commission Implementing Regulation (EU) 2025/1489 until 15 September 2026.
(5) Commission Directive 2006/39/EC included pirimicarb in Annex I to Council Directive 91/414/EEC as an active substance until 31 January 2017 and it was subsequently included in Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011. The approval of pirimicarb was extended nine times, most recently by Commission Implementing Regulation (EU) 2025/99 until 31 October 2026.
(6) Commission Directive 2006/64/CE included cyprodinil and fosetyl in Annex I to Council Directive 91/414/EEC as active substances until 30 April 2017 and they were subsequently included in Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011. The approvals of cyprodinil and fosetyl were extended eight times, most recently by Commission Implementing Regulation (EU) 2025/99, both until 31 October 2026.
(7) Commission Directive 2006/74/CE included dichlorprop-P in Annex I to Council Directive 91/414/EEC as an active substance until 31 May 2017 and it was subsequently included in Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011. The approval of dichlorprop-P was extended eight times, most recently by Commission Implementing Regulation (EU) 2025/99 until 31 October 2026.
(8) Commission Directive 2007/5/EC included formetanate in Annex I to Council Directive 91/414/EEC as an active substance until 30 September 2017 and it was subsequently included in Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011. The approval of formetanate was extended eight times, most recently by Commission Implementing Regulation (EU) 2025/99 until 30 September 2026.
(9) Commission Directive 2007/50/EC included beflubutamid in Annex I to Council Directive 91/414/EEC as an active substance until 30 November 2017 and it was subsequently included in Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011. The approval of beflubutamid was extended seven times, most recently by Commission Implementing Regulation (EU) 2023/918 until 31 October 2026.
(10) Commission Directive 2007/76/EU included fludioxonil and clomazone in Annex I to Council Directive 91/414/EEC as active substances until 31 October 2018 and they were subsequently included in Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011. The approvals of fludioxonil and clomazone were extended seven times each, most recently by Commission Implementing Regulation (EU) 2025/787, both until 30 September 2026.
(11) Commission Directive 2008/116/EC16 included aclonifen and metazachlor in Annex I to Council Directive 91/414/EEC as active substances until 31 July 2019 and they were subsequently included in Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011. The approvals of aclonifen and metazachlor were extended three and four times, respectively, most recently by Commission Implementing Regulation (EU) 2023/918, both until 31 October 2026.
(12) Commission Directive 2009/77/EC17 included dimethachlor and penconazole in Annex I to Council Directive 91/414/EEC as active substances until 31 December 2019 and they were subsequently included in Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011. The approvals of dimethachlor and penconazole were extended four times, most recently by Commission Implementing Regulation (EU) 2023/259218 , both until 15 October 2026.
(13) Commission Directive 2010/28/EU19 included metalaxyl in Annex I to Council Directive 91/414/EEC as an active substance until 30 June 2020 and it was subsequently included in Part A of the Annex to Commission Implementing Regulation (EU) No 540/2011. The approval of metalaxyl was extended twice, most recently by Commission Implementing Regulation (EU) 2023/918 until 30 September 2026.
(14) Commission Implementing Regulation (EU) No 151/2014 approved the active substance S-abscisic acid until 30 June 2024 and included it in Part B of the Annex to Commission Implementing Regulation (EU) No 540/2011. The approval of S-abscisic acid was extended once with Commission Implementing Regulation (EU) 2024/1892 until 15 September 2026.
(15) Commission Implementing Regulation (EU) No 193/2014 approved the active substance amisulbrom until 30 June 2024 and included it in Part B of the Annex to Commission Implementing Regulation (EU) No 540/2011. The approval of amisulbrom was extended with Commission Implementing Regulation (EU) 2024/1892 until 15 September 2026.
(16) Commission Implementing Regulation (EU) 2016/1414 approved the active substance cyantraniliprole until 14 September 2026 and included it in Part B of the Annex to Commission Implementing Regulation (EU) No 540/2011.
(17) Commission Implementing Regulation (EU) 2016/1425 approved the active substance isofetamid until 15 September 2026 and included it in Part B of the Annex to Commission Implementing Regulation (EU) No 540/2011.
(18) Commission Implementing Regulation (EU) 2016/142926 approved the active substance Bacillus amyloliquefaciens strain MBI 600 until 16 September 2026 and included it in Part B of the Annex to Commission Implementing Regulation (EU) No 540/2011.
(19) As the approvals of these active substances are likely to expire before decisions have been taken on their renewal as part of the ongoing renewal procedures, the Commission inquired with the rapporteur Member States concerned and the European Food Safety Authority (the ‘Authority’) on the reasons for the delays in the renewal procedures of these active substances. The Commission also inquired when the draft renewal assessment reports by the rapporteur Member States or the conclusions of the Authority could be expected to be finalised.
(20) The information available, including that provided by the rapporteur Member States and the Authority, shows that the reasons for the delays in each of these renewal procedures are beyond the control of the applicants.
[Se utkastet for hele fortalen.]